Branded Legacy, Inc. Signs Letter of Intent to Acquire Bio-Legacy Evaluative Group, Advancing Innovations in Intranasal Drug Delivery

Core Insights - Branded Legacy, Inc. has executed a non-binding Letter of Intent to acquire Bio-Legacy Evaluative Group for $1.5 million in Preferred D stock, aiming to enhance its position in the naloxone and vaccine markets [1][2][3] Company Overview - Branded Legacy, Inc. is a diversified holdings company focused on innovative health and wellness solutions, with a commitment to expanding its portfolio into high-growth sectors addressing global health crises [2][8] Acquisition Details - The acquisition involves 100% of Bio-Legacy Evaluative Group's equity interests, assets, intellectual property, and operations [1] - The Preferred D stock issued will have a two-year holding period and is convertible upon achieving a $40 million post-acquisition valuation [4] - A $1 million research and development budget has been committed for Bio-Legacy's initiatives, effective upon uplisting to the OTCQB market tier [4] Market Potential - The naloxone market is projected to grow from $371 million in 2022 to over $1.16 billion by 2032, with a CAGR of approximately 11.9% [3] - Bio-Legacy's intranasal delivery technology aims to simplify manufacturing and enhance dose precision, addressing current market limitations [3] Leadership Transition - Amin Janmohamed will assume the roles of CEO and Chairman of Branded Legacy post-acquisition, leveraging his extensive experience in pharmacy and clinical studies [5][6] Strategic Goals - The acquisition is expected to enhance Branded Legacy's competitive edge in the biotech and medical device sectors, positioning the company to capitalize on expanding markets [6] - Projected revenues for Bio-Legacy could reach up to $183.3 million by Year 5 under average growth scenarios [5]